kidney neoplasms/træthed

Linket gemmes på udklipsholderen

Vælg sorteringstype

Side 1 fra 84 resultater

Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

Pazopanib is a multitarget tyrosine kinase inhibitor used in the treatment of renal cancer and soft tissue sarcoma. Its use is commonly associated with a number of side effects, such as hemorrhagic diathesis, neutropenia, leukopenia, thrombocytopenia, nausea, vomiting, abdominal pain,

[Revision of therapeutic index for targeted treatment in kidney cancer: What if toxicity could predict efficacy?].

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

Since 2006, new treatments as targeted therapies (anti angiogenic and mTOR inhibitors) are prescribed in renal cell cancer. Toxicity of these treatments is well known by clinicians. Occurrence of these side effects has been associated with anti tumoral efficacy. High blood pressure, hypothyroïdie

Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

OBJECTIVE A prospective multicenter phase II trial was undertaken to define the activity of a low-dose subcutaneous regimen of interleukin-2 (IL-2) and interferon alfa-2a (IFN) in patients with metastatic renal cancer. METHODS Between December 1990 and October 1991, 42 patients with metastatic renal

A phase II study of gemcitabine at fixed infusion rate of 10 mg/m2/min with or without immunotherapy in advanced renal cancer.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

BACKGROUND Advanced renal cancer remains a challenge for oncologists since no treatment other than surgery has demonstrated a clear survival advantage. METHODS Gemcitabine was given to suitable patients at a fixed infusion rate of 10 mg/m2/min. Eighteen patients received concomitant immunotherapy,

Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

BACKGROUND Current first-line treatments for metastatic renal cell carcinoma (mRCC) include the multityrosine kinase inhibitors pazopanib and sunitinib. Both agents had similar progression-free survival (PFS) and overall survival (OS) in the COMPARZ trial (Comparing the Efficacy, Safety and

An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

BACKGROUND Both sunitinib and pazopanib are widely used as first line therapy in metastatic renal cancer (mRCC). The efficacy of these agents appears similar but they may have distinct toxicity profiles. In this study we compare the severity of symptomatic and asymptomatic toxicity associated with

A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

BACKGROUND The objective of this study was to verify previous reports of activity with gemcitabine plus a fluoropyrimidine in patients with metastatic renal cell cancer in a multiinstitutional setting. METHODS Eligibility included a Zubrod performance status from 0 to 2, no prior gemcitabine or

Single fraction radiosurgery for the treatment of renal tumors.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

OBJECTIVE High dose local stereotactic radiosurgery was performed in select patients to improve local tumor control and overall survival. We report on patients with renal tumors treated with single fraction robotic stereotactic radiosurgery. METHODS A total of 40 patients with a median age of 64

Interferon-alpha therapy of renal cancer.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

Thirty-three patients with renal cancer began treatment with human lymphoblastoid interferon (Wellferon) between August 1982 and February 1983. Interferon was administered as an i.m. injection at a dose of 5 X 10(6) units/sq m 3 times per week. Treatments were continued for at least 24 weeks in the

Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

OBJECTIVE Oblimersen is an 18-base oligodeoxynucleotide encoding antisense to the gene for bcl-2, an anti-apoptotic protein that is upregulated in renal and other cancers. This study was designed to evaluate the combination of oblimersen with alpha-Interferon in advanced renal cancer. Trial

A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

Protein kinase C (PKC) has a critical role in several signal transduction pathways, and is involved in renal cancer pathogenesis. Bryostatin-1 modulates PKC activity and has antitumour effects in preclinical studies. We conducted a multicentre phase II clinical trial in patients with advanced renal

Oxygen-ozone therapy as support and palliative therapy in 50 cancer patients with fatigue - A short report.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

Fatigue may be cause by all cancer treatments, maybe because the tissue damage or the build-up of dead cells derived products.At the Mede Clinic in Sacile, Pordenone, Italy, from February 2016 to May 2018 we studied 50 patients with cancer and fatigue (15

A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

BACKGROUND Everolimus (mammalian target of rapmaycin (mTOR) inhibitor) and dovitinib (vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF-2) inhibitor) demonstrate activity in metastatic clear cell renal cancer. The combination of these agents has a broad spectrum of

Therapeutic effect and adverse reaction of sorafenib in the treatment of advanced renal cancer.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

Efficacy and safety of sorafenib in patients with advanced renal cancer were evaluated. Seventy-four patients with advanced renal cancer treated with sorafenib + interferon from January 2010 to August 2013 were included as the observation group. Another 53 renal cancer patients treated with

Clinical features of kidney cancer in primary care: a case-control study using primary care records.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

BACKGROUND Kidney cancer accounts for over 4000 UK deaths annually, and is one of the cancer sites with a poor mortality record compared with Europe. OBJECTIVE To identify and quantify all clinical features of kidney cancer in primary care. METHODS Case-control study, using General Practice Research

Tidligere
1
2
3
4
5
6
Næste

Deltag i vores
facebook-side

Herbal & Natural Medicine

Den mest komplette database med medicinske urter understøttet af videnskab

Arbejder på 55 sprog
Urtekurer, der understøttes af videnskab
Urtegenkendelse ved billede
Interaktivt GPS-kort - tag urter på stedet (kommer snart)
Læs videnskabelige publikationer relateret til din søgning
Søg medicinske urter efter deres virkninger
Organiser dine interesser og hold dig opdateret med nyhedsundersøgelser, kliniske forsøg og patenter

Skriv et symptom eller en sygdom, og læs om urter, der kan hjælpe, skriv en urt og se sygdomme og symptomer, den bruges mod.
* Al information er baseret på offentliggjort videnskabelig forskning